Atossa Genetics Inc Market Cap ($20.06 Million)
Market Cap & Net Worth: Atossa Genetics Inc (ATOS)
Atossa Genetics Inc market cap. Atossa Genetics Inc (NASDAQ:ATOS) has a market capitalization of $20.06 Million ($20.06 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #24944 globally and #5316 in its home market, demonstrating a -4.90% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Atossa Genetics Inc's stock price $2.33 by its total outstanding shares 8611428 (8.61 Million). Also see Atossa Genetics Inc operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Atossa Genetics Inc Market Cap History (2015–2026)
Atossa Genetics Inc market cap history from 2015 to 2026. Data shows change from $496.02 Million to $20.06 Million (-30.76% CAGR). Check ATOS live share price for real-time trading data and today's change.
Index Memberships
Atossa Genetics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #699 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #2300 of 3165 |
Weight: Atossa Genetics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Atossa Genetics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Atossa Genetics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Atossa Genetics Inc net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
282149.18x
Atossa Genetics Inc's market cap is 282149.18 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $496.02 Million | $1.76K | -$15.76 Million | 282149.18x | N/A |
Competitor Companies of ATOS by Market Capitalization
Companies near Atossa Genetics Inc in the global market cap rankings as of November 5, 2026. Also see Atossa Genetics Inc (ATOS) total assets for a full breakdown of the balance sheet.
Key companies related to Atossa Genetics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Atossa Genetics Inc (2015–2026)
Market capitalization of Atossa Genetics Inc from 2015 to today. Between 2015 and today, Atossa Genetics Inc's market cap moved from $496.02 Million to $ 20.06 Million, with a yearly change of -30.76%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $20.06 Million | +294.92% |
| 2025 | $5.08 Million | -37.51% |
| 2024 | $8.13 Million | +7.28% |
| 2023 | $7.58 Million | +66.51% |
| 2022 | $4.55 Million | -66.97% |
| 2021 | $13.78 Million | +68.42% |
| 2020 | $8.18 Million | -39.49% |
| 2019 | $13.52 Million | +53.92% |
| 2018 | $8.78 Million | -67.68% |
| 2017 | $27.18 Million | -81.35% |
| 2016 | $145.71 Million | -70.62% |
| 2015 | $496.02 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Atossa Genetics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $20.06 Million USD |
| MoneyControl | $20.06 Million USD |
| MarketWatch | $20.06 Million USD |
| marketcap.company | $20.06 Million USD |
| Reuters | $20.06 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Atossa Genetics Inc
Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develop… Read more